RDTCF Stock Chart & Stats
$0.08
>-$0.01(-5.18%)
At close: 4:00 PM EDT
$0.08
>-$0.01(-5.18%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.15
Previous CloseN/A
Volume500.00
Average Volume (3M)722.00
Market Cap
$11.34M
Enterprise Value$20.79
Total Cash (Recent Filing)$14.65K
Total Debt (Recent Filing)$5.81M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding136,444,840
10 Day Avg. Volume300
30 Day Avg. Volume722
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-2.78
Price to Sales (P/S)7.19
P/FCF Ratio-73.51
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Delivery PlatformThe proprietary QuickStrip platform provides a differentiated drug-delivery capability that can be applied across pharmaceuticals, nutraceuticals, and other active compounds. A reusable technology base may support repeated formulation opportunities and licensing activity over the next several quarters.
Partnering-based Business ModelA partnering and licensing model can let Rapid Dose commercialize its delivery technology without building a large fully integrated manufacturing operation. Development fees, milestones, royalties, and product revenue also create several potential routes to monetize platform adoption.
Recent Positive Cash FlowPositive trailing-twelve-month operating and free cash flow marks an improvement from negative free cash flow in several prior annual periods. Although modest and potentially volatile, this indicates the business has recently generated some internal funding rather than consuming cash exclusively.
Bears Say
Shrinking Revenue And Weak EconomicsDeclining revenue combined with negative gross profit indicates that the current commercial base is not yet producing attractive underlying economics. Sustained pressure on sales and gross margin could limit reinvestment, weaken operating leverage, and delay a durable path to profitability.
Negative Shareholders’ EquityPersistently negative equity materially reduces financial flexibility and signals that liabilities exceed the recorded capital base. Meaningful debt relative to assets can further constrain funding choices, increase solvency risk, and make it harder to absorb setbacks over the next several quarters.
Persistent Substantial LossesLarge recurring losses, including net losses greater than revenue, show that the business has not yet converted its technology and commercial activity into sustainable earnings. This can require continued external financing and leaves less capacity to fund product development or market expansion internally.
Rapid Dose Therapeutics Corp News
RDTCF FAQ
What was Rapid Dose Therapeutics Corp’s price range in the past 12 months?
Rapid Dose Therapeutics Corp lowest stock price was <$0.01 and its highest was $0.15 in the past 12 months.
What is Rapid Dose Therapeutics Corp’s market cap?
Rapid Dose Therapeutics Corp’s market cap is $11.34M.
When is Rapid Dose Therapeutics Corp’s upcoming earnings report date?
Rapid Dose Therapeutics Corp’s upcoming earnings report date is Oct 22, 2026 which is in 41 days.
How were Rapid Dose Therapeutics Corp’s earnings last quarter?
Rapid Dose Therapeutics Corp released its earnings results on Jun 29, 2026. The company reported -$0.003 earnings per share for the quarter.
Is Rapid Dose Therapeutics Corp overvalued?
According to Wall Street analysts Rapid Dose Therapeutics Corp’s price is currently Overvalued.
Does Rapid Dose Therapeutics Corp pay dividends?
Rapid Dose Therapeutics Corp does not currently pay dividends.
What is Rapid Dose Therapeutics Corp’s EPS estimate?
Rapid Dose Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rapid Dose Therapeutics Corp have?
Rapid Dose Therapeutics Corp has 136,444,840 shares outstanding.
What happened to Rapid Dose Therapeutics Corp’s price movement after its last earnings report?
Rapid Dose Therapeutics Corp reported an EPS of -$0.003 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Rapid Dose Therapeutics Corp?
Currently, no hedge funds are holding shares in RDTCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rapid Dose Therapeutics Corp
Rapid Dose Therapeutics Corp., headquartered in Burlington, Canada, is a life sciences enterprise dedicated to developing advanced drug delivery technologies aimed at improving health results and individuals' quality of life. The company's flagship product is QuickStrip/PharmaStrip, an innovative oral, fast-dissolving film designed to swiftly introduce active compounds—such as pharmaceuticals, emulsified oils, and over-the-counter medicines—directly into the bloodstream. They offer specific QuickStrip variants like QuickStrip energy for caffeine delivery, QuickStrip B12 for vitamin B12 supplementation, and QuickStrip sleep for melatonin. Beyond its proprietary products, the firm also delivers comprehensive services encompassing product innovation, manufacturing, and consultation to industries including nutraceuticals, cannabis healthcare, and pharmaceutical production. Rapid Dose Therapeutics maintains a significant research collaboration with McMaster University, focusing on crafting enhanced biopolymer compositions for oral dissolvable thin films and investigating an orally administered vaccine candidate for COVID-19.